Who we are

Silengenics is developing precision RNAi therapeutics.

Our lead program, SIG-001, is a liver-targeted siRNA–GalNAc therapeutic in preclinical development, designed to silence a target at the intersection of atherogenic dyslipidemia and hepatic steatosis.